GLP-1 Drugs Explained: Semaglutide, Tirzepatide and More
GLP-1 has gone from a hormone most people had never heard of to the name behind some of the most talked-about medications in modern medicine. If you're trying to understand what these drugs actually are, rather than just which celebrity is rumored to use one, this guide walks through the biology, the main drugs in the class, and the honest trade-offs.
What GLP-1 Actually Is
GLP-1, short for glucagon-like peptide-1, is a hormone your own gut releases naturally after you eat. It tells your pancreas to release insulin, slows how fast your stomach empties, and signals your brain that you're full. GLP-1 receptor agonist medications are lab-made molecules that mimic this hormone, but they last far longer in the body than the natural version, which breaks down within minutes.
That difference in duration is the whole point. Natural GLP-1 gives you a brief signal after a meal. A once-weekly injectable version keeps that signal switched on around the clock, which is why the effects on appetite and blood sugar are so much stronger than anything your body produces on its own.
How the Mechanism Produces Weight Loss
Three overlapping effects explain most of what these drugs do.
Slower Digestion
Food moves more slowly from the stomach into the intestines, which extends the feeling of fullness after a meal and blunts blood sugar spikes.
Reduced Appetite
GLP-1 receptors in the brainstem and hypothalamus dial down hunger signals and food cravings, which is the mechanism behind the drop in appetite that most people notice within days.
Better Insulin Response
The pancreas releases insulin only when blood sugar is already elevated, which is one reason these drugs don't typically cause dangerously low blood sugar on their own.
We go deeper into the appetite piece specifically in why GLP-1 drugs reduce appetite, and into the blood sugar mechanism in how GLP-1 drugs affect blood sugar.
Semaglutide vs Tirzepatide: The Two Main Molecules
Almost every GLP-1 drug on the market today is one of two active ingredients, sold under different brand names depending on the approved use.
| Molecule | Brand Names | Mechanism | Notes |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus, oral Wegovy | GLP-1 receptor agonist only | The original blockbuster GLP-1; oral and injectable forms exist |
| Tirzepatide | Mounjaro, Zepbound | Dual GLP-1/GIP receptor agonist | Activates a second gut hormone receptor (GIP) alongside GLP-1, which is linked to greater average weight loss |
| Liraglutide | Victoza, Saxenda | GLP-1 receptor agonist only | An earlier, shorter-acting daily injection, largely superseded by weekly options |
The naming is confusing on purpose, in a sense. Manufacturers give the same molecule a different brand name for each FDA-approved use, so semaglutide is Ozempic when approved for diabetes and Wegovy when approved for weight management, even though the drug in the pen is essentially the same. We break this down in full in Ozempic vs Wegovy and Mounjaro vs Zepbound.
GLP-1 medications are typically delivered as once-weekly injector pens.
Side Effects and Real Risks
GLP-1 drugs are generally well tolerated, but they are not risk-free, and gastrointestinal side effects are common enough that anyone starting one should know what to expect.
Common and Serious Side Effects
- Very common: nausea, vomiting, diarrhea and constipation, especially during the first weeks or after a dose increase
- Common: fatigue, heartburn and abdominal discomfort
- Less common but serious: gallbladder problems, pancreatitis and, rarely, vision changes in people with diabetic retinopathy
- Muscle loss: a meaningful share of the weight lost on these drugs can be lean muscle mass rather than fat, which is why resistance training and adequate protein intake are commonly recommended alongside treatment
- These medications carry a boxed warning about thyroid C-cell tumors seen in rodent studies; people with a personal or family history of certain thyroid cancers should not take them
We cover several of these in dedicated guides: GLP-1 drugs and muscle loss, nausea, constipation, and gallbladder problems.
Who These Drugs Are For
GLP-1 medications are prescription drugs, and eligibility depends on the specific brand's FDA-approved indication. In general, diabetes-labeled drugs like Ozempic and Mounjaro are approved for adults with type 2 diabetes, while weight-management drugs like Wegovy and Zepbound are approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or sleep apnea.
They are not approved for cosmetic weight loss in people without a qualifying BMI or health condition, and they require ongoing medical supervision. What happens if you stop is its own important question, covered in what happens after stopping a GLP-1 drug.
How These Drugs Compare to Older Weight-Loss Medications
Before GLP-1 drugs, medication options for obesity were limited and comparatively modest in effect. Orlistat, which blocks fat absorption in the gut, typically produced 3% to 5% average weight loss and came with notoriously unpleasant gastrointestinal side effects. Phentermine, a stimulant-based appetite suppressant, is only approved for short-term use and produces smaller, less durable results.
The jump to 15% to 21% average body weight loss with semaglutide and tirzepatide respectively is what changed the entire conversation around obesity treatment, moving it from something addressed mainly through diet and exercise programs to something treated more like a chronic disease requiring ongoing medication, similar to how high blood pressure or diabetes is managed long-term.
What This Class of Drug Does Not Do
It is worth being clear about what GLP-1 drugs are not. They are not a cure for obesity in the sense that the underlying tendency toward weight regain typically returns once the medication is stopped, a pattern covered in detail in what happens after stopping a GLP-1 drug. They also do not replace the need for reasonable nutrition and activity, since the drugs work best, and the associated muscle loss is smallest, when combined with adequate protein intake and resistance exercise.
They are also not risk-free convenience drugs. The gastrointestinal side effects are common enough that a meaningful share of people discontinue treatment within the first year, and the serious but rarer risks, including gallbladder disease and pancreatitis, mean ongoing medical supervision is not optional.
A Brief History of GLP-1 Research
The scientific groundwork for these drugs goes back much further than the current boom suggests. Researchers first identified GLP-1's role in insulin regulation in the late 1980s, and the first GLP-1-based drug, exenatide, was approved for type 2 diabetes in 2005, derived originally from a compound found in Gila monster venom. It worked, but it required twice-daily injections and produced only modest weight loss as a side effect.
Semaglutide, developed by Novo Nordisk, was engineered specifically to last longer in the body, enabling once-weekly dosing and a stronger, more consistent effect on appetite. It was approved for diabetes as Ozempic in 2017, and the weight-loss data from those diabetes trials was striking enough that Novo Nordisk pursued a dedicated obesity trial program, leading to Wegovy's 2021 approval. Eli Lilly followed a similar path with tirzepatide, adding a second hormone receptor (GIP) to push the effect further, resulting in Mounjaro in 2022 and Zepbound in 2023.
The Bigger Picture: A Fast-Moving Field
The GLP-1 field has moved quickly even within 2026 alone. An oral tablet version of semaglutide (Wegovy pill) was approved in December 2025, followed by the first oral small-molecule GLP-1, orforglipron, in April 2026, both aimed at people who prefer a pill to a weekly injection. Meanwhile, next-generation injectable drugs in late-stage trials, particularly the triple-hormone agonist retatrutide, are showing even greater average weight loss than tirzepatide, with results in Phase 3 trials approaching the range typically seen with bariatric surgery.
If you're evaluating your options today, it helps to know the landscape is still shifting. We track the oral drugs specifically in oral GLP-1 weight-loss drugs explained, and the drugs still in the pipeline in next-generation weight-loss drugs explained.
Frequently Asked Questions
What does GLP-1 stand for?
GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by the gut after eating that helps regulate insulin release, digestion speed, and appetite.
Is semaglutide the same as Ozempic?
Yes. Semaglutide is the active ingredient; Ozempic, Wegovy and oral Rybelsus/Wegovy are all brand names for semaglutide, approved for different uses and at different doses.
Which is stronger, semaglutide or tirzepatide?
In head-to-head and cross-trial comparisons, tirzepatide (Mounjaro/Zepbound) has generally produced greater average weight loss than semaglutide (Ozempic/Wegovy), likely because it activates a second hormone receptor, GIP, in addition to GLP-1.
Are GLP-1 drugs safe long-term?
They have been studied for over a decade for diabetes and several years for weight loss, with a generally favorable safety profile, but they carry real risks including gastrointestinal side effects, gallbladder issues, and a boxed warning about thyroid tumors seen in animal studies. Long-term use should be supervised by a healthcare provider.
Key Takeaways
- GLP-1 drugs mimic a natural gut hormone to reduce appetite, slow digestion and improve blood sugar control
- Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two dominant molecules in the class
- Tirzepatide's dual GLP-1/GIP mechanism is linked to greater average weight loss than semaglutide alone
- Gastrointestinal side effects are common, especially during dose increases, and serious risks like pancreatitis are rare but real
- These are prescription medications that require medical supervision, not something to self-administer or obtain outside a licensed provider
More Health Guides, Written Clearly
Browse our full library of medically reviewed articles on diabetes, heart health, and weight management — all in plain, easy-to-understand language.
Explore All Health ArticlesSources and References
- Gallup National Health and Well-Being Index — GLP-1 Usage Reaches New High, 2026
- Stanford Medicine — GLP-1s 101: What the Science Says, 2026
- GoodRx — Comparing Ozempic, Wegovy, and Other GLP-1 Drugs
- Wharton, S., et al. — Daily oral GLP-1 receptor agonist orforglipron for adults with obesity, NEJM
- Westchester Medical Center Health Network — How GLP-1s Actually Work